Acta Neurologica Belgica

, Volume 115, Issue 4, pp 657–663 | Cite as

ADHD, autism and neuroradiological complications among phenylketonuric children in Upper Egypt

  • Khaled Saad
  • Yasser Elserogy
  • Ahmed A. Abdel rahman
  • Abdulrahman Abdullah Al-Atram
  • Ismail L. Mohamad
  • Tarek T. H. ElMelegy
  • Geir Bjørklund
  • Amira A. El-Houfy
Original Article


The aim of this study is to evaluate the neuropsychological status in a cohort of children with early and continuously treated phenylketonuria in Assiut, Upper Egypt. The study was implemented in seventy-eight phenylketonuria (PKU) children. Only 34 patients met the inclusion criteria. Investigated patients were evaluated according to detailed history, neurological examination, Childhood Autism Rating Scale, full scale Intelligence Quotient, attention deficit hyperactivity disorder, electroencephalography and magnetic resonance imaging (MRI). This study concluded that the prognosis for early diagnosed children with PKU treated from the first weeks of life is generally good. However, they are at increased risk for neurological complications and behavioral problems. So, neonatal screening for PKU is highly recommended in Egypt, for early detection and management. In addition, neuropsychological and MRI assessments in PKU children should be done.


Phenylketonuria ADHD Autism Children 


Conflict of interest

All authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


  1. 1.
    Følling A (1934) Über Ausscheidung von Phenylbrenztraubensäure im Harn als Stoffwechselanomalie in Verbindung mit Imbezillität. Hoppe Seylers Z Physiol Chem. 227:169–176CrossRefGoogle Scholar
  2. 2.
    MacLeod EL, Ney DM (2010) Nutritional management of phenylketonuria. Ann Nestlé (Engl). 68:58–69CrossRefGoogle Scholar
  3. 3.
    Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 376:1417–1427CrossRefPubMedGoogle Scholar
  4. 4.
    Brumm VL, Bilder D, Waisbren SE (2010) Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 99(Suppl 1):S59–S63CrossRefPubMedGoogle Scholar
  5. 5.
    Brumm VL, Azen C, Moats RA, Stern AM, Broomand C, Nelson MD, Koch R (2004) Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review. J Inherit Metab Dis 27:549–566CrossRefPubMedGoogle Scholar
  6. 6.
    Surtees R, Blau N (2000) The neurochemistry of phenylketonuria. Eur J Pediatr 159:S109–S113CrossRefPubMedGoogle Scholar
  7. 7.
    Scarabino T, Popolizio T, Tosetti M, Montanaro D, Giannatempo GM, Terlizzi R, Pollice S, Maiorana A, Maggialetti N, Carriero A, Leuzzi V, Salvolini U (2009) Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion. Radiol Med. 114:461–474CrossRefPubMedGoogle Scholar
  8. 8.
    Jones SJ, Turano G, Kriss A, Shawkat F, Kendall B, Thompson AJ (1995) Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. J Neurol Neurosurg Psychiatry 59:260–265PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Scriver CR, Kaufman S (2001) Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, 8th edn. McGraw-Hill, New York, pp 1667–1724Google Scholar
  10. 10.
    Williams RA, Mamotte CD, Burnett JR (2008) Phenylketonuria: an inborn error of metabolism. Clin Biochem Rev 29:31–40PubMedCentralPubMedGoogle Scholar
  11. 11.
    Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention (2012) Prevalence of autism spectrum disorders–Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ. 61(3):1–19Google Scholar
  12. 12.
    Kuehn BM (2007) CDC: autism spectrum disorders common. JAMA 297:940CrossRefPubMedGoogle Scholar
  13. 13.
    Manzi B, Loizzo AL, Giana G, Curatolo P (2008) Autism and metabolic diseases. J Child Neurol 23:307–314CrossRefPubMedGoogle Scholar
  14. 14.
    Saad K, Hammad E, Abdel-rahman AA, Sobhy KM (2013) Autistic symptoms in late diagnosed phenylketonuric children in Upper Egypt. J Neur Res 3(3–4):122–129Google Scholar
  15. 15.
    Chen CH, Hsiao KJ (1989) A Chinese classic phenylketonuria manifested as autism. Br J Psych 155:251–253CrossRefGoogle Scholar
  16. 16.
    Steiner CE, Acosta AX, Guerreiro MM, Marques-de-Faria AP (2007) Genotype and natural history in unrelated individuals with phenylketonuria and autistic behavior. Arq Neuropsiquiatr 65(2A):202–205CrossRefPubMedGoogle Scholar
  17. 17.
    Moss J, Howlin P (2009) Autism spectrum disorders in genetic syndromes: implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. J Intel Dis Res. 53:852–873CrossRefGoogle Scholar
  18. 18.
    Caglayan AO (2010) Genetic causes of syndromic and non-syndromic autism. Dev Med Child Neurol 52:130–138CrossRefPubMedGoogle Scholar
  19. 19.
    Antshel KM, Waisbren SE (2003) Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. J Abnorm Child Psychol 31:565–574CrossRefPubMedGoogle Scholar
  20. 20.
    Antshel KM (2010) ADHD, learning, and academic performance in phenylketonuria. Mol Genet Metab 99(S1):S52–S58CrossRefPubMedGoogle Scholar
  21. 21.
    Melika LK (1998) The Stanford Binet Intelligence Scale. Arabic Examiner’s Handbook, 4th edn. Dar El-Maref Publishing, CairoGoogle Scholar
  22. 22.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Association, Washington, DCGoogle Scholar
  23. 23.
    Schopler E, Reichller R, Renner BR (1994) The Childhood Autism Rating Scale CARS. Western Psychological Services, Los AngelesGoogle Scholar
  24. 24.
    Rellini E, Tortolani D, Trillo S, Carbone S, Montecchi F (2004) Childhood Autism Rating Scale CARS, and Autism Behavior Checklist ABC, correspondence and conflicts with DSM-IV criteria in diagnosis of autism. J Autism Dev Disord 34:703–708CrossRefPubMedGoogle Scholar
  25. 25.
    Perry A, Condillac RA, Freeman NL, Dunn-Geier J, Belair J (2005) Multi-site study of the Childhood Autism Rating Scale (CARS) in five clinical groups of young children. J Autism Dev Disord 355:625–634CrossRefGoogle Scholar
  26. 26.
    Pietz J, Dunckelmann R, Rupp A, Rating D, Meinck HM, Schmidt H, Bremer HJ (1998) Neurological outcome in adult patients with early-treated phenylketonuria. Eur J Pediatr 157:824–830CrossRefPubMedGoogle Scholar
  27. 27.
    Albrecht J, Garbade SF, Burgard P (2009) Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci Biobehav Rev 33:414–421CrossRefPubMedGoogle Scholar
  28. 28.
    Crossley LH, Anderson PJ (2010) Neuropsychological functioning in early-treated phenylketonuria—a review. Ann Nestlé (Engl). 68:78–88CrossRefGoogle Scholar
  29. 29.
    McCandless DW (2012) Epilepsy: animal and human correlations. Springer, New YorkCrossRefGoogle Scholar
  30. 30.
    González MJ, Gutiérrez AP, Gassió R, Fusté ME, Vilaseca MA, Campistol J (2011) Neurological complications and behavioral problems in patients with phenylketonuria in a follow-up unit. Mol Genet Metab 104:S73–S79Google Scholar
  31. 31.
    Yalaz K, Vanli L, Yilmaz E, Tokatli A, Anlar B (2006) Phenylketonuria in pediatric neurology practice: a series of 146 cases. J Child Neurol 21:987–990CrossRefPubMedGoogle Scholar
  32. 32.
    Thompson AJ, Tillotson AJ, Smith I et al (1993) Brain MRI changes in phenylketonuria; associations with dietary status. Brain. 116:811–821CrossRefPubMedGoogle Scholar
  33. 33.
    Cleary MA, Walter JH, Wraith JE, Jenkins JP, Alani SM, Tyler K, Whittle D (1994) Magnetic resonance imaging of the brain in phenylketonuria. Lancet 344:87–90CrossRefPubMedGoogle Scholar
  34. 34.
    Toft PB, Lou HC, Krägeloh-Mann I, Andresen J, Güttler F, Guldberg P, Henriksen O (1994) Brain magnetic resonance imaging in children with optimally controlled hyperphenylalaninaemia. J Inherit Metab Dis 17:575–583CrossRefPubMedGoogle Scholar
  35. 35.
    Weglage J, Pietsch M, Fünders B, Koch HG, Ullrich K (1995) Neurological findings in early treated phenylketonuria. Acta Paediatr 84:411–415CrossRefPubMedGoogle Scholar
  36. 36.
    Landvogt C, Mengel E, Bartenstein P, Buchholz HG, Schreckenberger M, Siessmeier T, Scheurich A, Feldmann R, Weglage J, Cumming P, Zepp F, Ullrich K (2008) Reduced cerebral fluoro-l-dopamine uptake in adult patients suffering from phenylketonuria. J Cereb Blood Flow Metab 28:824–831CrossRefPubMedGoogle Scholar
  37. 37.
    Goldman-Rakic PS (1998) The cortical dopamine system: role in memory and cognition. Adv Pharmacol 42:707–711CrossRefPubMedGoogle Scholar
  38. 38.
    Arnold GL, Vladutiu CJ, Orlowski CC, Blakely EM, DeLuca J (2004) Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 27(2):137–143CrossRefPubMedGoogle Scholar
  39. 39.
    Posner J, Gorman D, Nagel BJ (2009) Tyrosine supplements for ADHD symptoms with comorbid phenylketonuria. J Neuropsychiatry Clin Neurosci 21:228–230CrossRefPubMedGoogle Scholar
  40. 40.
    Baieli S, Pavone L, Meli C, Fiumara A, Coleman M (2003) Autism and phenylketonuria. J Autism Dev Disord 33:201–204CrossRefPubMedGoogle Scholar
  41. 41.
    Zafeiriou DI, Ververi A, Vargiami E (2007) Childhood autism and associated comorbidities. Brain Dev 29:257–272CrossRefPubMedGoogle Scholar
  42. 42.
    Okado N (1999) Mechanisms for formation and maintenance of synapses mediated by biogenic amines: pathogenesis and therapy of mental retardation and developmental disabilities by genetic and epigenetic factors. Kaibogaku Zasshi. 74:351–362PubMedGoogle Scholar
  43. 43.
    Anderson PJ, Wood SJ, Francis DE, Coleman L, Warwick L, Casanelia S, Anderson VA, Boneh A (2004) Neuropsychological functioning in children with early-treated phenylketonuria: impact of white matter abnormalities. Dev Med Child Neurol 46:230–238CrossRefPubMedGoogle Scholar
  44. 44.
    Anderson PJ, Leuzzi V (2010) White matter pathology in phenylketonuria. Mol Genet Metab 99:3–9CrossRefGoogle Scholar
  45. 45.
    Christ SE, Steiner RD, Grange DK, Abrams RA, White DA (2006) Inhibitory control in children with phenylketonuria. Dev Neuropsychol. 30:845–864CrossRefPubMedGoogle Scholar
  46. 46.
    Anderson PJ, Wood SJ, Francis DE, Coleman L, Anderson V, Boneh A (2007) Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels? Dev Neuropsychol. 32(2):645–668CrossRefPubMedGoogle Scholar

Copyright information

© Belgian Neurological Society 2015

Authors and Affiliations

  • Khaled Saad
    • 1
  • Yasser Elserogy
    • 2
  • Ahmed A. Abdel rahman
    • 2
  • Abdulrahman Abdullah Al-Atram
    • 3
  • Ismail L. Mohamad
    • 1
  • Tarek T. H. ElMelegy
    • 4
  • Geir Bjørklund
    • 5
  • Amira A. El-Houfy
    • 6
  1. 1.Department of PediatricsAssiut UniversityAsyûtEgypt
  2. 2.Department of NeuropsychiatryAssiut UniversityAsyûtEgypt
  3. 3.Department of Psychiatry, College of MedicineAlmajmaah UniversityAl Majma’ahKSA
  4. 4.Department of Clinical PathologyAssiut UniversityAsyûtEgypt
  5. 5.Council for Nutritional and Environmental MedicineMo i RanaNorway
  6. 6.Department of Community Health NursingAssiut UniversityAsyûtEgypt

Personalised recommendations